Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Carcinoma, Hepatocellular 35Carcinoma, Non-Small-Cell Lung 32Colorectal Neoplasms 19Esophageal Squamous Cell Carcinoma 18Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 11Cholangiocarcinoma 11Head and Neck Neoplasms 10Small Cell Lung Carcinoma 9Lung Neoplasms 9Esophageal Neoplasms 9Triple Negative Breast Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Carcinoma 7Urinary Bladder Neoplasms 6Recurrence 6Pancreatic Neoplasms 6Neoplasms 6Colonic Neoplasms 6Melanoma 5Hodgkin Disease 5Biliary Tract Neoplasms 4Adenocarcinoma of Lung 4Sarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neoplasm Metastasis 3NSCLC 3Locally Advanced Rectal Cancer 3Liver Neoplasms 3

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × tislelizumab × Clear all
NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Fudan University

Phase 2 Unknown
98 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05861635 2023-05-17

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 4 Unknown
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡